Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V M Macaulay

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Cancer Research|April 15, 1990
Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cellsV M Macaulay, M J Everard, J D Teale, et al.
British Journal of Cancer|May 1, 1996
Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supplyC H Thompson, V M Macaulay, K J O'Byrne, et al.
Oncogene|May 9, 2007
The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinomaJ S P Yuen, M E Cockman, M Sullivan, et al.
BMC Cancer|December 13, 2012
Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinomaB P Fairfax, S Pratap, I S D Roberts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1999
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusionsV M Macaulay, K J O'Byrne, M P Saunders, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumorsV M Macaulay, M R Middleton, A S Protheroe, et al.
British Journal of Cancer|July 17, 1998
Phase I study of the mitomycin C analogue BMS-181174V M Macaulay, K J O'Byrne, J A Green, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Cancer Research|April 15, 1990
Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cellsV M Macaulay, M J Everard, J D Teale, et al.
British Journal of Cancer|May 1, 1996
Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supplyC H Thompson, V M Macaulay, K J O'Byrne, et al.
Oncogene|May 9, 2007
The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinomaJ S P Yuen, M E Cockman, M Sullivan, et al.
BMC Cancer|December 13, 2012
Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinomaB P Fairfax, S Pratap, I S D Roberts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1999
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusionsV M Macaulay, K J O'Byrne, M P Saunders, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumorsV M Macaulay, M R Middleton, A S Protheroe, et al.
British Journal of Cancer|July 17, 1998
Phase I study of the mitomycin C analogue BMS-181174V M Macaulay, K J O'Byrne, J A Green, et al.
Pageof 3